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Abstract
Background: Gut derived lipid factors have been implicated in systemic injury and inflammation but the precise pathways
involved are unknown. In addition, dietary fat intake and obesity are independent risk factors for the development of
colorectal cancer. Here we studied the severity of experimental colitis and the development of colitis associated cancer
(CAC) in mice with an inducible block in chylomicron secretion and fat malabsorption, following intestine-specific deletion
of microsomal triglyceride transfer protein (Mttp-IKO).
Methodology/Principal Findings: Mttp-IKO mice exhibited more severe injury with ,90% mortality following dextran
sodium sulfate (DSS) induced colitis, compared to ,20% in controls. Intestinal permeability was increased in Mttp-IKO mice
compared to controls, both at baseline and after DSS administration, in association with increased circulating levels of TNFa.
DSS treatment increased colonic mRNA expression of IL-1b and IL-17A as well as inflammasome expression in both
genotypes, but the abundance of TNFa was selectively increased in DSS treated Mttp-IKO mice. There was a 2-fold increase
in colonic tumor burden in Mttp-IKO mice following azoxymethane/DSS treatment, which was associated with increased
colonic inflammation as well as alterations in cytokine expression. To examine the pathways by which alterations in fatty
acid abundance might interact with cytokine signaling to regulate colonic epithelial growth, we used primary murine
myofibroblasts to demonstrate that palmitate induced expression of amphiregulin and epiregulin and augmented the
increase in both of these growth mediators when added to IL-1bor to TNFa.
Conclusions: These studies demonstrate that Mttp-IKO mice, despite absorbing virtually no dietary fat, exhibit augmented
fatty acid dependent signaling that in turn exacerbates colonic injury and increases tumor formation.
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Introduction
The continued epidemic of obesity and its associated comor-
bidities has fueled interest in understanding the pathways and
mediators involved, particularly in relation to inflammation and
cancer. Obesity and its related metabolic complications have been
demonstrated to play a role in a number of cancers, including
colorectal cancer (CRC) and consequently dietary modification
and weight control are viewed as key modifiable risk factors [1].
However, the precise mechanisms and pathways by which obesity
contributes to CRC risk are still incompletely understood and are
likely to include alterations in systemic inflammation and cytokine
signaling, insulin resistance as well as local and systemic effects of
altered nutrient uptake including fatty acids, cholesterol and bile
acids [2]. Because of its importance as an energy source, dietary fat
intake has been a target for intervention as a strategy to mitigate
the effects of obesity and inflammation on CRC risk [3].
In addition to the role for obesity and fat intake in modulating
inflammation and CRC risk, there is emerging information
suggesting that the small intestine plays an important role as a
mediator in the inflammatory response to systemic sepsis [4,5]. In
this scenario, it has been suggested that the small intestine secretes
lipid products derived from luminal digestion, which are then
transported in mesenteric lymphatics, where they induce organ
failure at distant sites [6,7]. Other work has reinforced this gut-
lymph hypothesis by demonstrating that ligation of the mesenteric
duct (thereby eliminating delivery of chylomicrons from the
intestine into the systemic circulation) abrogates the systemic
effects of shock, findings that point to the importance of lipid
mediators arising from the intestine in the pathogenesis of systemic
inflammation [8,9]. Other work has implicated lipoproteins as
vehicles for transporting growth factors and morphogens, includ-
ing mammalian Wnt3, suggesting a more fundamental role for
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lipid transport in the regulation of epithelial growth and
proliferation [10].
In this study, we have examined the role of intestinal
chylomicron secretion in order to understand the role of intestinal
lipid transport in the pathogenesis of colonic inflammation and
colitis associate cancer (CAC). We recently demonstrated that
mice with conditional intestine-specific deletion of microsomal
triglyceride transfer protein (Mttp-IKO) develop virtually complete
block of intestinal absorption [11] and exhibit a survival advantage
when challenged with Pseudomonas aeruginosa, the most common
cause of gram negative pneumonia [12]. Those findings raised the
possibility that blocking intestinal chylomicron secretion might
also attenuate the effects of chemical induced experimental colitis
and in turn abrogate colorectal cancer development following
azoxymethane/dextran sodium sulfate (AOM/DSS) challenge
[13]. Our findings, however, revealed that Mttp-IKO mice
developed worse colonic injury and increased tumor burden.
Furthermore, we found that altered fatty acid signaling may play a
key role in promoting these phenotypes.
Materials and Methods
Animals
Mttpflox/flox villin-Cre-ERT2 (Mttp-IKO) mice (along with litter-
mate controls) were used for these studies, in a background of
,75% C57BL/6 and ,25% 129/SvJ. Cre recombinase expres-
sion in villus epithelial cells was induced by five daily intraper-
itoneal injections of 1 mg tamoxifen (Sigma), as described
previously [11]. Experiments were performed on mice consuming
a regular low fat rodent chow. Experimental colitis was induced by
administration of 2.5% dextran sodium sulfate (DSS) (MW
40,000–50,000, Cat#9011-18-1, Affymetrix, Inc, Cleveland,
Ohio.), for the indicated times in the figure legends and weighed
daily. CAC was induced by injection of 8 week old mice with
10 mg/kg body weight azoxymethane (AOM, Sigma) followed by
three cycles (5 days) of DSS starting at 5th(2%), 26th (2.5%) and
46th (2.5%) day after AOM injection, minor modifications of the
protocol used by others [14]. Mice were sacrificed at 9 weeks after
AOM injection and tissues collected for analysis. All animal studies
were approved by the Animal Studies Committees of Washington
University School of Medicine (#20100146) and were conducted
in strict accordance with the National Institutes of Health
guidelines for the use of laboratory animals.
Histomorphological analyses
Samples of small intestine and colon were fixed and embedded
for sectioning and hematoxylin and eosin (H&E) staining. Where
indicated, intestinal sections were stained for lipid droplets using
osmium tetroxide as described [12] Histologic scoring of DSS
injury was undertaken and quantitated using the parameters
described [15]. Intestinal proliferation was examined in mice
injected with 5-Bromo-29deoxyuridine (BrdU) (200 ml volume,
5 mg/ml diluted in normal saline; Sigma), 2 hours prior to
sacrifice. Samples were processed for BrdU staining as described
[12]. Analysis of colon tumor burden was undertaken using
samples fixed in 10% formalin (Sigma) and pinned for scoring by
an investigator blinded to genotype. Each sample was photo-
graphed using a Nikon SMZ800 dissecting microscope and a
Photometrics CooLSNAPcf camera (Imaging Processing Services).
The area of each section was determined and the size of tumors
quantitated using Metavue software (Molecular Devices). H&E
sections were also reviewed by a pathologist (IN), blinded to
genotype.
Intestinal permeability and cytokine assays
Intestinal permeability was determined following injection of
FITC labeled dextran (FD-4, MW 4000, Sigma). Control and
Mttp-IKO mice were gavaged with FD-4 (400 mg/Kg body
weight), prior to and 7 days after 2.5% DSS treatment and sera
were collected 4 hour later. Serum FITC was measured on a
fluorimeter (Synergy HT, BioTekH) at excitation 485/20, emission
528/20. For LPS determinations, sera were diluted 1:10 and
heated at 70uC for 15 minutes to inactive inhibitors. LPS was then
measured using the LAL chromogenic endotoxin quantitation kit
according the manufacturer’s instructions (ThermoScientific,
Rockford, IL). Serum TNFa and IL-1b were quantitated by
ELISA using kits purchased from BD Biosciences (San Jose, CA)
or R&D systems (Minneapolis, MN) following the manufacturers’
instructions.
Real time quantitative polymerase chain reaction
Total RNA was isolated from intestinal tissues using Trizol
either under standard protocols or for samples treated with DSS,
using the modification described by Kerr and colleagues [16].
RNAs were quantitated using primer pairs (sequences available
upon request) designed by Primer express software (Applied
Biosystems). Relative mRNA abundance is expressed relative to
control mice without DSS treatment, normalized to GAPDH.
Colonic lipid content, Fecal lipid content and protein
expression
Total lipids were extracted from feces as well as from proximal
colon, as previously described [11]. Triglyceride (TG), total
cholesterol (TC) and free fatty acid (FFA) were measured
enzymatically using Wako kits (Wako Chemicals, Richmond,
VA). Western blotting was conducted in standard fashion using
antibodies whose source is indicated in the relevant figure legend.
For colonic TNFa and IL1b content samples of descending colon
were homogenized in buffer containing 20 mM Tris (pH 7.4),
1 mM Sodium orthovanadate, 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1% Triton, 50 mM Sodium fluoride, 50 mM b-
glycerophosphate and 16 Complete mini protease inhibitor
cocktail (Roche, Mannhein, Germany). TNFa and IL1b levels
were measured in clarified supernatants using the ELISA kits
described above and normalized to protein concentration.
Primary murine intestinal myofibroblasts
Myofibroblasts were isolated from C57BL/6 wild type mice as
described [17] and 16105 cells per well were seeded in 6-well
plates and cultured overnight. The phenotype of these cells was
verified by positive staining for smooth muscle actin and vimentin
and negative staining for desmin and cytokeratin [13,17]. These
myofibroblasts cells were then cultured for 12 hours in DMEM
containing 0.25% FBA and 0.6% Fatty acid free bovine serum
albumin (BSA, A8806, Sigma), supplemented with either buffer
alone (BSA, Control), 200 mM Palmitate–BSA (PAL), TNFa at
100 ng/ml (TNFa) (R&D), IL1b at 10 ng/ml (IL1b) (R&D) or
combinations of 200 mM Palmitate–BSA plus TNFa 100 ng/ml
(TNFa+ PAL) or 200 mM Palmitate –BSA and IL1b 10 ng/ml
(IL1b+ PAL), as indicated in the legend. These studies were all
performed on myofibroblasts at passage 6–8. Sodium palmitate
was conjugated with fatty acid free BSA at ratio of 2:1 (Palmitate:
BSA), to make a 3 mM palmitate-BSA stock solution. Total RNA
was extracted from individual samples and mRNAs quantitated as
described above.
Increased Colitis and CAC in Mttp-IKO Mice
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Statistical Analysis
Multiple group comparisons of continuous data sets were
performed using one-way analysis of variance followed by post-hoc
t-test using Prism 4.0 (GraphPad Software, San Diego, CA) and
Microsoft Excel. Data are reported as means 6 SEM. Survival
studies were analyzed via the log-rank test. A p value ,0.05 was
considered to be statistically significant.
Results
Increased severity of DSS colitis in Mttp-IKO mice
We administered 2.5% DSS in drinking water for 12 days in
order to evaluate the impact on overall survival by genotype. Our
findings revealed thatMttp-IKO mice exhibit accelerated death and
markedly reduced survival (1/10) compared to control mice (9/11)
Figure 1A. The augmented injury phenotype in Mttp-IKO mice
was associated with greater weight loss in shorter (7 days)
experiments (Figure 1C) and a delayed return to baseline weight
(Figure 1B), along with reduced colon length (Figure 1D, E). There
was also more severe histologic injury as evidenced by increased
lamina propria inflammation and crypt drop-out in the descending
colon in Mttp-IKO mice at both 5 days (Figure 2A, B, E) and at 7
days (Figure 2C, D, E) and reduced cellular proliferation as
evidenced by decreased BrdU incorporation (Figure 2 F).
DSS administration does not induce macroscopic small
intestinal injury in Mttp-IKO mice and is not associated
with colonic lipid accumulation
Our previous studies demonstrated that blocking chylomicron
secretion from the intestine of Mttp-IKO mice results in massive
lipid engorgement with villus distortion [11], raising the possibility
that the high mortality encountered following DSS administration
might reflect gross damage in the small intestine of these mice.
However, this was not the case. As seen in Figure 3 A-D, we
observed the expected lipid accumulation in small intestinal villi in
Mttp-IKO mice but there was no gross or histological evidence of
ulceration in any region of the small intestine following 7 days of
DSS treatment. In addition, since Mttp is expressed in the colon of
mice (albeit at low levels [18,19]) we explored the possibility that
colonic lipid accumulation might contribute to the phenotype
observed in Mttp-IKO mice. However, this again was not the case.
As seen in Figure 3E-H, while we detected abundant lipid droplet
accumulation in the small intestine of Mttp-IKO mice (as previously
noted [11]) there were only rare, scattered osmium staining lipid
droplets seen in the colon of Mttp-IKO mice and there was no
accumulation of triglyceride, cholesterol or free fatty acid within
colonic mucosa as detectable by enzymatic assay (Figure 3I).
Increased intestinal permeability in Mttp-IKO mice and
the role of an adaptive stress response
While the findings above imply that there are no gross
alterations in villus integrity in Mttp-IKO mice, we explored the
Figure 1. Increased colonic injury in DSS treated Mttp-IKO mice. A. Decreased survival of Mttp-IKO (n = 10) versus littermate controls (n = 12).
8–10 weeks mice were fed 2.5% DSS in drinking water for 12 days and followed up to 25 days. **p,0.01. B. Weight recovery curve after one cycle of
DSS. Mice (n = 4 mice per group) were fed 2.5% DSS for 7 days and weighed every 1–3 days up to 25 days after the 1st day of DSS treatment. *p,0.05.
C. Weight loss after 7days DSS treatment, n = 10–12 mice per genotype. Data are presented as mean%6 SEM of initial weight. *p,0.05, **p,0.01 D.
Representative images of gross appearance of colon from control and Mttp IKOmice after 7 days DSS treatment. E. Colon length at 0, 5 and 7 days on
2.5% DSS. Data are mean 6 SE of 4–9 mice per group.*p,0.05.
doi:10.1371/journal.pone.0067819.g001
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possibility that more subtle alterations might be associated with
barrier dysfunction. To address this possibility, we administered
FITC labeled dextran by gavage to mice of both genotypes, either
before or after 7 days of DSS administration. Our findings
revealed that serum FITC levels were significantly higher in Mttp-
IKO mice under both conditions (Figure 4A). These findings
suggest that there is altered barrier function at baseline in Mttp-
IKO mice that becomes further impaired in the setting of DSS
injury. We next considered the possibility that the increased
intestinal permeability phenotype in Mttp-IKO mice might in part
reflect alterations in the expression of integral membrane proteins
involved in tight junction maintenance and whose altered
expression has been linked to defects in human inflammatory
bowel disease [20,21]. We found that expression of HNF4a, ZO-1
and Lamb1 was decreased at baseline in the small intestine of
Mttp-IKO mice and was decreased following DSS treatment,
particularly in control mice (Figure 4B). There was a correspond-
ing decrease in ZO-1 expression in the colon upon DSS treatment
with similar responses in control and Mttp-IKO mice (Figure 4C).
We also examined parameters of the unfolded protein response
(UPR) and integrated stress response pathways in the small
intestine and colon of both genotypes and the impact of DSS
exposure. Those findings demonstrated increased baseline expres-
sion of Grp78 and Chop in the small intestine of Mttp-IKO mice
(Figure 4B), as previously noted [22]. However, DSS treatment
failed to produce a further increase in any of these stress markers,
but rather tended to reduce expression of Grp78 and Chop in the
small intestine of Mttp-IKO mice (Figure 4B). By contrast, there
were no baseline changes in UPR mRNAs in the colon of Mttp-
IKO mice, but DSS treatment resulted in increased abundance of
Figure 2. Increased inflammation and decreased proliferation in DSS-treatedMttp-IKOmice. A. and B. Representative histological images
of comparable regions of distal colon from control (A.) and Mttp-IKO mice (B.) after 5 days of DSS treatment. Panels A and B show increased mucosal
injury in Mttp-IKO mice characterized by increased lamina propria inflammation extending to the submucosa with loss of crypts. C. and D.
Representative histologic images of comparable regions of descending colon from control (C.) and Mttp-IKO mice (D.) after 7 days DSS treatment.
Panels C and D show an increase in lamina propria inflammation, focal cryptitis characterized by neutrophilic infiltration and focal crypt drop-out in
Mttp-IKO mice. Bars indicate 100 mm. E. Quantitative estimate of histological damage (n = 5–7 mice per group). F. BrdU positive crypt cells in rectal
mucosa. Data were the mean 6 SEM of n= 5–6 mice per group. *p,0.05.
doi:10.1371/journal.pone.0067819.g002
Increased Colitis and CAC in Mttp-IKO Mice
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Xbp-1s in both genotypes (Figure 4C). These findings suggest that
there is no baseline UPR response in the colon of Mttp-IKO mice.
To examine the possibility that an adaptive ER stress response
might influence the injury phenotype observed in Mttp-IKO mice,
we treated mice with the chemical chaperone tauroursodeoxy-
cholic acid (TUDCA) since previous studies have shown that this
strategy attenuates the UPR in metabolic stress conditions in mice
[22,23]. These findings reveal that TUDCA treatment failed to
rescue the severe phenotype of DSS treated Mttp-IKO mice and if
anything led to accelerated death in these animals (Figure 4D).
These findings together lead us to conclude that the features of ER
stress and the UPR noted in the small intestine of Mttp-IKO mice
Figure 3. Morphology and lipid accumulation in intestine and colon of control and DSS treated Mttp-IKO mice. A-D. Representative
H&E staining of small intestine from Control and Mttp-IKO mice either without DSS treatment (A. Control-0 and B. Mttp-IKO-0) or after 7 days DSS
treatment (C. Control-7 and D. Mttp-IKO-7). Small intestine from Mttp-IKO mice (B and D) shows the villus lipid accumulation (vacuolar structure in
H&E staining), but no significant injury or inflammation after 7 days DSS treatment (D vs B). E-H. Representative Osmium tetroxide staining of lipid
droplets in small intestine (E and F) and Colon (G and H) without DSS treatment. Lipid droplets appear as brown images (arrows). Note the abundant
lipids droplets in Mttp-IKO small intestinal enterocytes (F), by contrast with only scattered lipid droplets in Mttp-IKO colonic epithelial cells (H). I.
Colonic lipids were extracted from control and Mttp-IKO mice without DSS treatment and lipid species (TG, TC and FFA) measured. The data are
presented as the mean 6 SEM of 4–5 mice per group.
doi:10.1371/journal.pone.0067819.g003
Increased Colitis and CAC in Mttp-IKO Mice
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are adaptive in nature and that abrogation of this response leads to
worse injury.
Enhanced colonic inflammation in Mttp-IKO mice in
response to DSS injury
We observed the expected increase in expression of several
cytokine mRNAs in the colon of DSS treated mice, including IL-
1b, IL-17A and Nlrp3, with comparable induction in both
genotypes (Figure 5A). However we observed a greater increase in
TNFa expression in the colon of DSS treated Mttp-IKO mice
compared to controls (Figure 5A). We also examined serum levels
of LPS, IL-1b and TNFa, which have been previously associated
with intestinal injury in mice treated with DSS [14,24]. Those
findings revealed that serum TNFa levels were consistently
elevated in Mttp-IKO mice, both at baseline and following DSS
treatment while serum levels of LPS and IL-1b were more variable
(Figure 5B-D).
Colonic injury and inflammation is associated with
increased susceptibility to CAC in Mttp-IKO mice
A substantial body of data suggests that inflammation is a major
driver of tumorigenesis and work suggests a causative link
mediated via pathways involving inflammatory cytokine signaling
[25,26]. Given the propensity of Mttp-IKO mice to manifest a more
severe phenotype in response to DSS mediated injury, we asked
whether this increased colonic inflammation was associated with
an altered colonic tumor burden following administration of
azoxymethane followed by three cycles of DSS (Figure 6A). The
findings reveal greater tumor multiplicity (Figure 6B) and overall
tumor burden (Figure 6C, D) (verified by pathologic examination
by a pathologist blinded to genotype) in Mttp-IKO mice in
association with increased cellular proliferation as evidenced by
BrdU incorporation (Figure 6E, F).
Inflammatory signals coupled with altered fatty acid
signaling drive growth mediator secretion in Mttp-IKO
mice
In order to understand in more depth the mechanisms
underlying the proliferative phenotype observed in the colon of
Mttp-IKO mice in response to AOM/DSS, we again examined the
expression patterns of IL-1b and TNFa. We observed increased
mRNA abundance of IL-1b in Mttp-IKO mice (Figure 7A) and a
trend to increased IL-1b protein expression (Figure 7B). The
expression of TNFa mRNA was comparable by genotype but we
observed a significant increase in TNFa protein levels in colonic
tissue from Mttp-IKO mice (Figure 7B). These findings again
support the hypothesis that an altered inflammatory response
likely contributes to the increased tumor burden observed in Mttp-
IKO mice.
To explore the mechanisms at play in this response, we
undertook an examination of possible mediators of this pro-
proliferative phenotype. Transcript profiling revealed no signifi-
cant changes in mRNA expression of several candidate mediators
(Figure 7A), but there was a trend to increased amphiregulin
protein expression and an increase in phospho-Akt abundance
(Figure 7C, D). These findings suggested to us that the secretion of
mediators from intestinal myofibroblasts might play a role in
growth modulation via paracrine pathways. In support of this
possibility there is work showing a role for stromal myofibroblast
production of amphiregulin and epiregulin in promoting colon
tumor growth in the setting of inflamed human colon [27]. Our
approach was guided by earlier findings demonstrating that small
intestinal epithelial cells from Mttp-IKO mice undergo lipotoxic
Figure 4. Impaired intestinal barrier and ER stress in Mttp-IKO
mice. A. Mttp-IKO and control mice either before DSS or 7 days after
DSS treatment were orally administered FITC-dextran and serum levels
measured 4 hrs later. Data are the mean 6 SEM of 7–8 mice per
group.*P,0.05. B. and C. mRNA expression of genes related to ER
stress and epithelial barrier functioin in small intestine and colon. mRNA
expression was measured by QPCR and expressed as fold change
compared to non-DSS treated control mice after normalized to internal
control Gapdh. Data are presented as the mean 6 SEM of 4–5 mice per
group. D. The effect of TUDCA on survival proportion of Control and
Mttp-IKO mice on DSS. 8–10 week old mice were treated with TUDCA or
saline intraperitoneally during simultaneous administration of DSS
(2.5%) in drinking water for 12 days. n = 5–9 each group. *p,0.05.
doi:10.1371/journal.pone.0067819.g004
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injury following short term high fat feeding [22]. Based on those
observations, we suspected that the sustained growth promoting
effects of intestinal Mttp deletion were potentially mediated by
myofibroblasts.
In order to explore this possibility in more detail, we turned to
primary murine intestinal myofibroblasts in order to examine
amphiregulin and epiregulin regulation. We first established that
fecal lipid content was increased as a result of fat malabsorption in
Mttp-IKO mice, as previously documented [11]. In particular, we
demonstrated increased fecal free fatty acid (FFA) abundance as
well as increased content of cholesterol and phospholipid in Mttp-
IKO mice (Figure 7E). We determined that the fecal FFA
concentration in control mice (,60 mmol/g) was similar to that
reported recently [28]. We focused our attention on the abundant
saturated fatty acids, selecting palmitic acid as an initial target in
which to examine the regulation of both amphiregulin and
epiregulin [29]. Our findings demonstrate striking upregulation of
amphiregulin and epiregulin mRNA in primary murine intestinal
myofibroblasts by 200 mM palmitate (Figure 7E). Furthermore, the
known induction of amphiregulin and epiregulin by TNFa and IL-
1b [30] was further enhanced by the inclusion of palmitate
(Figure 7E). These findings suggest that fatty acids play a role in
modifying growth responses in conjunction with other known
mediators. In line with this suggestion we demonstrated increased
small intestinal expression of amphiregulin expression in Mttp-IKO
mice following exposure to a high fat western diet (Figure 7F, G).
Figure 5. Increased colonic and systemic inflammation in Mttp-IKO mice. A. mRNA expression of genes related to inflammation in
descending colon of control and Mttp-IKO mice before and after 7 days DSS treatment. mRNA was measured by QPCR and expressed as fold changes
compared to non-DSS-treated control mice after normalized to Gapdh. Data are presented as the mean6 SEM of 5–9 mice per group. *p,0.05. B.-D.
Serum cytokines in control and Mttp-IKO mice. Blood was collected from control and Mttp-IKO mice before or 7 days after DSS treatment. Serum LPS
(B), IL1b (C) and TNFa (D) levels were measured as described in Methods. Data are the mean 6 SEM of 8–10 mice per group. *p,0.05.
doi:10.1371/journal.pone.0067819.g005
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Figure 6. Increased formation of colitis-associated tumors in AOM/DSS treatedMttp-IKOmice. A. Upper panel: Schematic overview of the
AOM/DSS protocol (detail in Methods). Mice were sacrificed 12 days after the last cycle of DSS. n = 13–15 mice each group. Lower panel: Percent
weight change during AOM-DSS treatment. B. Representative colonic photos. C. Number of colorectal tumors per mouse induced by AOM-DSS
treatment. D. Tumor burden in AOM-DSS treated control and Mttp-IKO mice. Data from panels D. are expressed as means 6 SEM of tumor area
normalized to the total colonic area, n = 9–10 mice each group. E. and F. Increased polyp proliferation by BrdU staining. (E) is a representative photo,
upper panel is a control polyp, lower panel is from a Mttp-IKO polyp. (F) is the bar graph of mean 6 SEM (n = 5–6 mice per group). * p,0.05.
doi:10.1371/journal.pone.0067819.g006
Increased Colitis and CAC in Mttp-IKO Mice
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Figure 7. Altered production of growth mediators in Mttp-IKO mice. A. Altered mRNA expression of genes related to inflammation and
growth. Gene expression in AOM/DSS-treated descending colon was measured by QPCR and expressed as fold change compared to control mice
after normalization to Gapdh. Data are mean6 SEM (n = 4 each group). *p,0.05. B. Protein content of IL1b and TNFa in homogenates of descending
colon from AOM/DSS-treated control and Mttp-IKO mice was measured by ElISA. Data are mean 6 SEM (n = 4 each group). *p,0.05. C. Western blot
analysis of amphiregulin (Areg), (1:1000 dilution of primary antibody from Thermo Fisher Scientific, Cat#RB-258); Akt (1:1000 of primary antibody
from Cell Signaling, Cat#9272); p-Akt (1:1000 of primary antibody from Cell Signaling, Cat# 9271) in homogenates of samples prepared (Methods)
from tissues noted above in B. D. Western blot was quantitated by Kodak image station 440 and Carestream MI SE software. Bar graph reflects the
mean 6 SEM of relative expression compared to control after normalization to Gapdh. E. Fecal lipid species in chow-fed control and Mttp-IKO mice.
Total fecal lipids were extracted and cholesterol (Chol), triglycerides (TG), phospholipids (PL), and free fatty acid (FFA) quantitated enzymatically. Lipid
content is presented as mg/g feces and FFA content is also presented as mmol/g feces (inset). Data are mean 6 SEM (n= 4–5 per group) **p,0.01. F.
mRNA abundance of Areg and Ereg in primary intestinal myofibroblasts after the indicated stimulation. Myofibroblasts were stimulated with
indicated factors for 12 hours. Gene (mRNA) expression was measured by QPCR and expressed as fold change compared to control cells after
normalization to Gapdh. Experiments were performed twice with triplicates for each experiment. Data are presented as mean 6 SEM. The difference
between values by group is indicated by a different letter to indicate statistical significance (p,0.05 or greater). G. Western blot analysis of Areg
protein expression in intestinal mucosa homogenates from control and Mttp-IKO mice on western diet for 2 weeks.
doi:10.1371/journal.pone.0067819.g007
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Taken together, the findings strongly suggest that increased
colonic fatty acid availability, produced by defective small
intestinal chylomicron assembly and the consequent block in
normal lipid absorption, exacerbates inflammatory and other
adaptive pathways that increase colonic proliferation.
Discussion
The findings in this report indicate that blocking chylomicron
secretion from the small intestine is associated with increased
severity of chemical (DSS) colitis and leads to increased tumor
burden in a model of CAC. The mechanisms and pathways
mediating these phenotypes include alterations in intestinal barrier
function with increased permeability and increased serum levels of
TNFa, coupled with activation of myofibroblast secretion of
growth factors mediated at least in part through altered fatty acid
signaling. Together the findings link aspects of intestinal lipid
metabolism with intestinal inflammation and also to pathways that
promote development of colorectal cancer. Some of these core
observations merit more detailed discussion.
Previous studies have implicated lipid-derived factors secreted
from the small intestine as key components in mediating distal
organ failure in systemic sepsis [8,9] although the precise lipid
components and lipoprotein particles involved (chylomicrons, low
or high density lipoprotein) are yet to be determined. Other work
has demonstrated that bacterial LPS absorption by the small
intestine involves chylomicron formation as evidenced by dimin-
ished serum LPS levels in animals treated with Pluronic L-81,
which functions within enterocytes to block chylomicron forma-
tion [31]. Here we observed that serum LPS levels tended to
increase following DSS treatment but we found no differences
between control and Mttp-IKO mice. By contrast, we found
elevated serum levels of TNFa in Mttp-IKO mice, both at baseline
and following DSS treatment, suggesting that blocking chylomi-
cron formation was associated with increased production or
altered turnover of this proinflammatory cytokine in the setting of
acute chemical colitis. Further work will be required to resolve the
cellular origins of TNFa and to address the important questions of
production and clearance rates of this cytokine in DSS mediated
colonic injury. Nevertheless, our findings are consistent with other
work that has implicated lipid-dependent alterations in intestinal
delivery of dietary antigens that modulate systemic responses,
including the release of inflammatory mediators from adipose
tissue [32,33].
Our recent findings demonstrated that Mttp-IKO mice were
protected against pneumonia-associated sepsis induced intestinal
injury and exhibited decreased mortality [12], which led us to
speculate that blocking intestinal chylomicron secretion might
actually be protective against other models associated with
systemic inflammations. However, our findings demonstrated the
opposite conclusion. Here we show that Mttp-IKO mice have a far
worse outcome when challenged in a model of chemical (DSS)
colitis. The apparent discordance in these outcomes lead us to
suggest that blocking chylomicron assembly and secretion may
protect animals from the secondary manifestations of intestinal
injury only when the source of sepsis involves extraintestinal tissues
(such as the lung). In the setting of pneumonia-associated sepsis,
for example, Mttp-IKO mice exhibit a compensatory increase in
hepatic HDL production [12]. By contrast, the current findings
strongly imply that blocking chylomicron formation and decreas-
ing dietary lipid absorption exacerbates the systemic effects of
inflammatory stimuli associated with colonic injury.
Another consideration in attempting to understand the path-
ways by which blocking chylomicron secretion exaggerates the
inflammation associated with colonic injury is that the genetic
pathways involved in Mttp-dependent lipid delivery into the
endoplasmic reticulum [34] overlap with Mttp-dependent path-
ways involved in lipid antigen processing. In this alternative
setting, Mttp has been shown to play a key role in lipidating CD1
antigen presenting family members [35]. This is relevant because
lipid antigen loading onto CD1d molecules is critical for
presentation to natural killer T (NKT) cells [36]. In relation to
the current findings, it is worth noting that human subjects with
abetalipoproteinemia (ABL) (in whom the MTTP gene is defective)
have been shown to exhibit defective CD1 function as a result of
impaired lipid antigen loading [37]. It is also worth noting that
while the incidence of colorectal cancer in ABL subjects is
unknown, there is a case report of ileal adenocarcinoma in a
patient with mild ABL [38]. Thus a confluence of findings suggest
that Mttp may function in pathways beyond dietary lipid
absorption and might conceivably play a role in the pathogenesis
of intestinal inflammatory and protective processes mediated by
CD1 dependent pathways [39]. In keeping with this suggestion,
studies demonstrated that Mttp deletion was protective against
experimental oxazalone-induced colitis, which is dependent on the
presumptively haptenated antigen being presented via invariant
NKT cells [40]. Those studies however did not address the specific
role of intestinal epithelial Mttp deletion, but rather used an Mx-1
(interferon-inducible) Cre [40]. The question of whether intestine-
specific Mttp deletion (as in the current study) exhibits the same
protective phenotype as that observed using the interferon
inducible system employed in those earlier studies will await
clarification.
The current findings also raise the question of how dietary fat
and intestinal lipid metabolism might influence inflammation and
pathways relevant to the pathogenesis of colorectal cancer. It has
been shown for example that mice chronically fed high fat diets
exhibit increased mortality in some models of sepsis [41] while
other studies demonstrated that high fat diets induce low grade
endotoxemia in both experimental animals and in studies using
intestinal cell culture [42]. Recent studies in otherwise healthy
human subjects has further shown that feeding a western-style high
fat diet produces features of systemic inflammation, including
endotoxemia [43]. In keeping with these findings, other studies in
obese subjects demonstrated that diet-induced weight loss led to
reductions in serum cytokines associated with systemic inflamma-
tion (including TNFa, IL-1b), [44]. Taken together, the findings
from in vitro studies together with studies using experimental
animal models as well as human studies reinforce the concept that
strategies including reducing dietary fat intake may attenuate the
pro-inflammatory state associated with obesity and in turn reduce
the risk of colorectal cancer. It bears emphasis that the current
studies were undertaken in two genotypes of mice fed low fat
rodent chow, suggesting that the increased fatty acid flux in Mttp-
IKO mice resulted from the unabsorbed lipid rather than from
increased dietary fat intake or from obesity (since Mttp-IKO mice
are lean), or from increased colonic accumulation of neutral lipid.
In this regard, we validated fecal FFA content in control, chow-fed
mice (,60 mmol/g, Figure 7E) was similar to that recently
reported [28]. In addition, those authors demonstrated that
palmitic acid represented the dominant saturated FA species found
in feces [28]. Extrapolating from their findings, we estimate that
palmitic acid is present in control, chow-fed mouse feces at a
concentration of ,20 millimolar [28]. These are important
considerations in evaluating the effects of palmitic acid as used
in the current studies. We selected a concentration (200 mM)
previously shown in cell models to stimulate lipotoxic adaptive
responses [29]. Our findings demonstrate a significant induction of
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epiregulin and amphiregulin expression in intestinal myofibro-
blasts, even at FFA concentrations log orders lower than found
within the colonic lumen. Based upon these findings, it would be of
interest to examine the effects if any of short-term exposure to high
fat diets on colorectal cancer development or progression in Mttp-
IKO mice.
Finally, our findings raise the possibility that there may be other
adverse effects of Mttp deletion beyond lipid malabsorption.
Pharmacologic compounds that block Mttp activity are currently
in clinical trials, including some that are by design intestine-
specific [45–49]. Our findings raise the concern that human
subjects consuming these agents might be more susceptible to
inflammatory conditions affecting the intestine and potentially also
at greater risk of developing colorectal tumors.
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